Literature DB >> 21320549

The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule.

Martin O Ota1, Adebayo Akinsola, John Townend, Martin Antonio, Godwin Enwere, David Nsekpong, Abdoulie Bojang, Mark Saaka, R L Burton, Akram Zaman, David Goldblatt, Richard A Adegbola.   

Abstract

The immunogenicity and impact on carriage of fewer doses of pneumococcal conjugate vaccine (PCV7) followed by booster with pneumococcal polysaccharide vaccine (PPV) were investigated. 684 infants were assigned randomly to one of the three groups that received one (A), two (B) or three (C) doses of PCV7 between 2 and 4 months of age, plus PPV at 10 months. Following primary vaccination protective antibody titers of >0.35 μg/ml against the PCV7 serotypes combined increased significantly with the number of PCV7 doses, 44% vs. 77% vs. 94% (p<0.001), and correlated positively with the opsonophagocytic indices, but negatively with nasopharyngeal carriage of pneumococcus. The differences in antibody responses and pneumococcal carriage between the groups diminished following booster with PPV, implying that administration of one or two doses of PCV7, with a booster dose of PPV might lower the cost of protection against IPD in young children in resource poor countries.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320549     DOI: 10.1016/j.vaccine.2011.01.098

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016.

Authors:  Tolulope A Adebanjo; Tracy Pondo; David Yankey; Holly A Hill; Ryan Gierke; Mirasol Apostol; Meghan Barnes; Susan Petit; Monica Farley; Lee H Harrison; Corinne Holtzman; Joan Baumbach; Nancy Bennett; Suzanne McGuire; Ann Thomas; William Schaffner; Bernard Beall; Cynthia G Whitney; Tamara Pilishvili
Journal:  Pediatrics       Date:  2020-02-13       Impact factor: 7.124

2.  Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study.

Authors:  Grant A Mackenzie; Isaac Osei; Rasheed Salaudeen; Ousman Secka; Umberto D'Alessandro; Ed Clarke; Jonas Schmidt-Chanasit; Paul V Licciardi; Cattram Nguyen; Brian Greenwood; Kim Mulholland
Journal:  Trials       Date:  2022-01-15       Impact factor: 2.728

3.  A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial.

Authors:  Grant A Mackenzie; Isaac Osei; Rasheed Salaudeen; Ilias Hossain; Benjamin Young; Ousman Secka; Umberto D'Alessandro; Arto A Palmu; Jukka Jokinen; Jason Hinds; Stefan Flasche; Kim Mulholland; Cattram Nguyen; Brian Greenwood
Journal:  Trials       Date:  2022-01-24       Impact factor: 2.728

Review 4.  Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers.

Authors:  Cynthia G Whitney; David Goldblatt; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 5.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.

Authors:  Maria Deloria Knoll; Daniel E Park; T Scott Johnson; Subash Chandir; Bareng Aletta S Nonyane; Laura Conklin; Katherine E Fleming-Dutra; Jennifer D Loo; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 6.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage.

Authors:  Katherine E Fleming-Dutra; Laura Conklin; Jennifer D Loo; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 7.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.

Authors:  Laura Conklin; Jennifer D Loo; Jennifer Kirk; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

8.  Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.

Authors:  William S Pomat; Anita H J van den Biggelaar; Suparat Phuanukoonnon; Jacinta Francis; Peter Jacoby; Peter M Siba; Michael P Alpers; John C Reeder; Patrick G Holt; Peter C Richmond; Deborah Lehmann
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

9.  Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.

Authors:  Adebayo K Akinsola; Martin O C Ota; Godwin C Enwere; Brown J Okoko; Syed M A Zaman; Mark Saaka; Ekpedeme D Nsekpong; Aderonke A Odutola; Brian M Greenwood; Felicity T Cutts; Richard A Adegbola
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

10.  Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.

Authors:  Stefania P Bjarnarson; Hreinn Benonisson; Giuseppe Del Giudice; Ingileif Jonsdottir
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.